1. Introduction {#sec1-cancers-12-02180}
===============

Radiotherapy is a definitive treatment for prostate cancer (PCa). Prostate-specific antigen (PSA) is the biomarker used for post-treatment surveillance of PCa patients \[[@B1-cancers-12-02180],[@B2-cancers-12-02180]\]. In curative cases, PSA levels decrease gradually over a period of more than five years after radiotherapy and reach a nadir. In a subset of patients, however, PSA levels fluctuate and show a temporal increase called the PSA bounce \[[@B3-cancers-12-02180]\]. It is difficult to appropriately diagnose PSA increase post-radiotherapy as the bounce; therefore, the PSA increase post-radiotherapy can be the cause of severe anxiety in both PCa patients and clinicians. Misinterpretation may even endanger patients by leading to unnecessary salvage treatment in cases meeting the definition of biochemical failure. PSA bounce can occur in relation to various radiotherapy modalities, including external beam radiotherapy (EBRT), stereotactic body radiotherapy (SBRT), low dose-rate brachytherapy (LDR-BT), and high dose-rate brachytherapy (HDR-BT) \[[@B4-cancers-12-02180],[@B5-cancers-12-02180]\]. As these radiotherapy modalities use different radiation sources, doses, and fractionation, as well as delivery techniques, they can exert different biological effects on the tumor and the prostate. However, the characteristics of PSA bounce in relation to different radiotherapy modalities remain unclear. To address this issue, we performed a meta-analysis of the characteristics of PSA bounce.

2. Results {#sec2-cancers-12-02180}
==========

A systematic literature review was performed to identify studies reporting PSA bounce post-radiotherapy (see Materials and Methods for details) ([Figure 1](#cancers-12-02180-f001){ref-type="fig"}). The search identified 50 studies including 26,258 patients, which were included in the analysis ([Table 1](#cancers-12-02180-t001){ref-type="table"}) \[[@B6-cancers-12-02180],[@B7-cancers-12-02180],[@B8-cancers-12-02180],[@B9-cancers-12-02180],[@B10-cancers-12-02180],[@B11-cancers-12-02180],[@B12-cancers-12-02180],[@B13-cancers-12-02180],[@B14-cancers-12-02180],[@B15-cancers-12-02180],[@B16-cancers-12-02180],[@B17-cancers-12-02180],[@B18-cancers-12-02180],[@B19-cancers-12-02180],[@B20-cancers-12-02180],[@B21-cancers-12-02180],[@B22-cancers-12-02180],[@B23-cancers-12-02180],[@B24-cancers-12-02180],[@B25-cancers-12-02180],[@B26-cancers-12-02180],[@B27-cancers-12-02180],[@B28-cancers-12-02180],[@B29-cancers-12-02180],[@B30-cancers-12-02180],[@B31-cancers-12-02180],[@B32-cancers-12-02180],[@B33-cancers-12-02180],[@B34-cancers-12-02180],[@B35-cancers-12-02180],[@B36-cancers-12-02180],[@B37-cancers-12-02180],[@B38-cancers-12-02180],[@B39-cancers-12-02180],[@B40-cancers-12-02180],[@B41-cancers-12-02180],[@B42-cancers-12-02180],[@B43-cancers-12-02180],[@B44-cancers-12-02180],[@B45-cancers-12-02180],[@B46-cancers-12-02180],[@B47-cancers-12-02180],[@B48-cancers-12-02180],[@B49-cancers-12-02180],[@B50-cancers-12-02180],[@B51-cancers-12-02180],[@B52-cancers-12-02180],[@B53-cancers-12-02180],[@B54-cancers-12-02180],[@B55-cancers-12-02180]\]. The number of studies and patients stratified by modality is summarized in [Table S1](#app1-cancers-12-02180){ref-type="app"}. Among the 50 studies, eight were prospective observational studies \[[@B14-cancers-12-02180],[@B15-cancers-12-02180],[@B17-cancers-12-02180],[@B32-cancers-12-02180],[@B39-cancers-12-02180],[@B40-cancers-12-02180],[@B41-cancers-12-02180],[@B50-cancers-12-02180]\] and the others were retrospective observational studies.

A meta-analysis showed that the rate of PSA bounce for all studies was 31% (95% confidence interval (CI), 28--33%) ([Figure 2](#cancers-12-02180-f002){ref-type="fig"}). The bounce rates according to modality were as follows: 34% (95% CI, 30--37%) for LDR-BT, 36% (95% CI, 29--42%) for HDR-BT, 22% (95% CI, 19--25%) for EBRT, 28% (95% CI, 23--32%) for SBRT, 28% (95% CI, 26--31%) for EBRT followed by boost irradiation, and 56% (95% CI, 47--64%) for carbon-ion radiotherapy ([Figure 2](#cancers-12-02180-f002){ref-type="fig"}). For all studies, bounce amplitude was 1.3 ng/mL (95% CI, 1.1--1.4 ng/mL); time to bounce occurrence was 18 months (95% CI, 17--20 months); nadir value was 0.5 ng/mL (95% CI, 0.4--0.6 ng/mL); and time to nadir was 33 months (95% CI, 22--43 months). The results of the meta-analysis stratified by modality are summarized in [Table 2](#cancers-12-02180-t002){ref-type="table"}, and the original forest plots are shown in [Figures S1--S4](#app1-cancers-12-02180){ref-type="app"}. Nadir value was higher in bounce-positive patients than in bounce-negative patients for EBRT, SBRT, and CIRT, whereas time to nadir was greater in bounce-positive than in bounce-negative patients regardless of modality ([Table 3](#cancers-12-02180-t003){ref-type="table"}).

The rate and characteristics of the bounce showed significant heterogeneity among the studies ([Table 2](#cancers-12-02180-t002){ref-type="table"}). To find the cause of the heterogeneity, we performed univariate meta-regression analysis. Age, radiotherapy modality, use of androgen deprivation therapy (ADT), and risk classification were selected as the covariates for meta-regression based on previous studies reporting that these factors affect the bounce kinetics \[[@B4-cancers-12-02180],[@B5-cancers-12-02180]\]. The heterogeneity in the bounce rate was attributed to modality (29.7%), age (20.2%), and risk classification (12.2%) ([Figure 3](#cancers-12-02180-f003){ref-type="fig"}A,B, [Table 3](#cancers-12-02180-t003){ref-type="table"}). Regarding bounce amplitude, age was a significant cause of heterogeneity ([Figure 3](#cancers-12-02180-f003){ref-type="fig"}C, [Table 3](#cancers-12-02180-t003){ref-type="table"}). For time to bounce occurrence, modality was a significant cause of heterogeneity ([Table 4](#cancers-12-02180-t004){ref-type="table"}).

3. Discussion {#sec3-cancers-12-02180}
=============

The strength of this study is that this is the first meta-analysis to investigate the characteristics of PSA bounce post-radiotherapy. We report the rate, amplitude, nadir, and time course of the bounce for different modalities including brachytherapy, EBRT, SBRT, and CIRT. We also report that the bounce occurs more frequently and with greater amplitude in brachytherapy than in EBRT, and a younger age is associated with a higher incidence and greater amplitude of the bounce. These findings have been extensively reported in mono-institutional studies, e.g., the large-scale study by Romesser \[[@B46-cancers-12-02180]\], which were validated here for the first time by meta-analysis. From this standpoint, the results of the present study are useful for post-radiotherapy surveillance of prostate cancer patients to help oncologists and patients interpret temporal PSA increases post-treatment.

The limitations of this study, on the other hand, are the following. First, the studies analyzed were extremely heterogeneous regarding clinical factors such as dose, fractionation, bounce rate according to ADT usage, and risk classification, which was difficult to control in a meta-analysis design. In particular, the ADT strategy (i.e., the presence or absence of adjuvant or neoadjuvant use) should have affected post-radiotherapy PSA kinetics to a large extent, which was difficult to adjust by study design. Second, we were not able to analyze the PSA kinetics post-radiotherapy stratified by bounce positivity except for nadir and time to nadir. This was because extraction of the corresponding data from the original articles was technically impossible; i.e., the original articles did not contain the PSA kinetics data linked to specific clinical variables (e.g., age and risk) in a form that we can compute in the meta-analysis. Third, we were unable to perform multivariate meta-regression analysis because of the small number of studies. Fourth, most of the studies included had a retrospective design, and no randomized studies were identified. Finally, studies on particle therapy were rarely identified (i.e., one study on CIRT and no studies on proton therapy).

The molecular mechanisms underlying PSA bounce remain to be elucidated. Studies have shown that PSA is released from both tumor tissues and the normal prostate glands after irradiation \[[@B48-cancers-12-02180]\]. Radiation-induced antitumor immunity may contribute to the release of PSA from tumor tissues. For example, Yamamoto et al. reported intra-tumoral infiltration of CD3- and CD8-positive lymphocytes in bounce-positive patients \[[@B56-cancers-12-02180]\]. In the present meta-analysis, the bounce was more prevalent after brachytherapy and SBRT than after EBRT. In addition, the bounce rate for CIRT was strikingly high, although only one study was analyzed. These findings may be explained by the highly concentrated dose delivery by brachytherapy, SBRT, and CIRT compared with that of EBRT. Evidence suggests that a high, single-fractionated dose induces antitumor immunity efficiently \[[@B57-cancers-12-02180]\], partially by promoting DNA damage response signaling \[[@B58-cancers-12-02180]\]. In addition, the properties of carbon ions as high linear energy transfer radiation to efficiently induce antitumor immunity (e.g., induction of HMGB1 \[[@B59-cancers-12-02180]\], OX40L, CD40, ICAM-1, and MHC-1, and suppression of PD-L1 \[[@B60-cancers-12-02180]\]) might contribute to the high bounce rate for CIRT. Another possible explanation for the higher bounce rate associated with brachytherapy, SBRT, and CIRT is that the highly concentrated doses delivered by these modalities destroy the normal prostate glands more efficiently. Kirilova et al. showed an increase in metabolism indicative of inflammation in the normal prostate gland of patients experiencing bounce, which supports this notion \[[@B61-cancers-12-02180]\].

In addition to modality, the meta-regression results indicated that younger age is associated with greater bounce occurrence and amplitude. This is consistent with the findings of the systematic literature review, in which 29 of the 50 papers analyzed identify younger age as a predictor of bounce. Yamamoto et al. suggested that this may be related to the higher immunocompetency in younger patients \[[@B56-cancers-12-02180]\]. Further research is warranted to elucidate immunologic responses of PCa and the prostate glands after radiotherapy.

4. Materials and Methods {#sec4-cancers-12-02180}
========================

4.1. Endpoint Definition {#sec4dot1-cancers-12-02180}
------------------------

The primary endpoint of this study was the rate of PSA bounce. Secondary endpoints included the characteristics of bounce, i.e., bounce amplitude, time to occurrence, nadir value, and time to nadir. Definitions of these endpoints are listed in [Table S2](#app1-cancers-12-02180){ref-type="app"}.

4.2. Inclusion and Exclusion Criteria {#sec4dot2-cancers-12-02180}
-------------------------------------

The inclusion criteria were as follows: (i) an original clinical study reporting on radiotherapy for PCa; (ii) available rate of PSA bounce; and (iii) bounce defined as an increase in PSA over a cutoff of 0.2 ng/mL followed by a spontaneous decrease to or below the pre-bounce nadir \[[@B19-cancers-12-02180]\]. The exclusion criteria were as follows: (i) manuscript written in languages other than English; (ii) full manuscript not available; (iii) subgroup analysis of a given reported cohort; (iv) follow-up shorter than 24 months.

4.3. Study Selection {#sec4dot3-cancers-12-02180}
--------------------

A systematic literature search based on preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines \[[@B62-cancers-12-02180]\] was performed on 20 March 2020, using two databases, Medline and Web of Science. The search strategy and population-intervention-comparison-outcome metrics \[[@B63-cancers-12-02180]\] are described in [Tables S3 and S4](#app1-cancers-12-02180){ref-type="app"}, respectively. The search results were combined using the bibliographic management software Mendeley Desktop version 1.19.4 (Mendeley, London, UK), and duplicates were eliminated. Two investigators (N.D.M.D. and T.Oi.) independently reviewed all records in the following three steps. In step 1, the titles of all records were reviewed to detect potentially relevant records. In step 2, the abstracts of all records that passed step 1 were reviewed to detect potentially relevant records. In step 3, the entire manuscripts of all records that passed step 2 were examined if they contained extractable data for the primary endpoint.

4.4. Data Extraction {#sec4dot4-cancers-12-02180}
--------------------

From the studies identified in [Section 4.3](#sec4dot3-cancers-12-02180){ref-type="sec"}, two investigators (N.D.M.D. and T.Oi.) independently extracted the following data: primary and secondary endpoints, radiotherapy modality, age, risk classification \[[@B64-cancers-12-02180]\], the use of ADT, and follow-up period.

4.5. Quality Assessment {#sec4dot5-cancers-12-02180}
-----------------------

Two investigators (N.D.M.D. and T.Oi.) independently confirmed that the methodological quality of the included studies was adequate based on the Quality Assessment Tool for Case Series Studies published by the National Heart, Lung, and Blood Institute-National Institute of Health, U.S. \[[@B65-cancers-12-02180]\]. For [Section 4.3](#sec4dot3-cancers-12-02180){ref-type="sec"}, [Section 4.4](#sec4dot4-cancers-12-02180){ref-type="sec"}, and [Section 4.5](#sec4dot5-cancers-12-02180){ref-type="sec"}, decisions were made based on discussion by the two investigators to resolve disagreements on the review results.

4.6. Statistical Analysis {#sec4dot6-cancers-12-02180}
-------------------------

Radiotherapy modalities were classified into six groups as follows: iLDR-BT (^103^Pd, ^125^I, or ^131^Cs), HDR-BT (^192^Ir), EBRT (three-dimensional conformal radiotherapy or intensity-modulated radiation therapy), SBRT (using CyberKnife or linac), EBRT+boost (using LDR-BT, HDR-BT, or SBRT), and CIRT. Meta-analysis of bounce (binomial data) was performed using *metaprop*, a command of Stata (MP 13, StataCorp, College Station, TX, USA) \[[@B66-cancers-12-02180]\]. Meta-analysis of the characteristics of bounce (continuous variables) was performed using *metan*, a Stata command. For the datasets that lacked the mean and standard deviation to be pooled, these values were estimated from the sample size, median, range, and/or interquartile range, as reported previously \[[@B67-cancers-12-02180]\]. A random-effects model was used considering a high extent of inter-study heterogeneity examined using *X^2^* and *I^2^* statistics \[[@B68-cancers-12-02180]\]. Meta-regression was performed to analyze the effect of clinical factors on inter-study heterogeneity in effect size using *metareg*, a Stata command \[[@B69-cancers-12-02180]\]. To construct the *metareg* command for bounce rate, logit prevalence and its standard error were used \[[@B70-cancers-12-02180],[@B71-cancers-12-02180]\]; for the remaining PSA kinetics outcomes, mean and standard error were used \[[@B72-cancers-12-02180]\]. Results with a *p*-value \< 0.05 were interpreted as significant.

5. Conclusions {#sec5-cancers-12-02180}
==============

This is the first study to report the results of meta-analysis and meta-regression of PSA bounce post-radiotherapy. Meta-analysis of 50 studies including 26,258 patients showed that the rate of PSA bounce for all studies was 31% (95% CI, 28--33%); bounce amplitude was 1.3 ng/mL (95% CI, 1.1--1.4 ng/mL); time to bounce occurrence was 18 months (95% CI, 17--20 months); nadir value was 0.5 ng/mL (95% CI, 0.4--0.6 ng/mL); and time to nadir was 33 months (95% CI, 22--43 months). The bounce occurred more frequently and with greater amplitude in brachytherapy than in EBRT. Univariate meta-regression showed that younger age is associated with a higher incidence and greater amplitude of bounce. These data will be useful for post-radiotherapy surveillance of PCa patients to help oncologists and patients interpret temporal PSA increases post-treatment.

The following are available online at <https://www.mdpi.com/2072-6694/12/8/2180/s1>. Table S1: The number of studies and patients according to radiotherapy modality, Table S2: Definition of endpoints, Table S3: Search strategy, Table S4: PICO metrics, Figure S1: Meta-analysis of the amplitude of prostate-specific antigen (PSA) bounce after radiotherapy. ES, effect size; CI, confidence interval; LDR-BT, low dose-rate brachytherapy; HDR-BT, high dose-rate brachytherapy; EBRT, external beam radiotherapy; SBRT, stereotactic body radiotherapy; CIRT, carbon ion radiotherapy. Figure S2: Meta-analysis of the time to occurrence of prostate-specific antigen (PSA) bounce after radiotherapy. ES, effect size; CI, confidence interval; LDR-BT, low dose-rate brachytherapy; HDR-BT, high dose-rate brachytherapy; EBRT, external beam radiotherapy; SBRT, stereotactic body radiotherapy; CIRT, carbon ion radiotherapy. Figure S3: Meta-analysis of prostate-specific antigen (PSA) nadir values after radiotherapy. ES, effect size; CI, confidence interval; LDR-BT, low dose-rate brachytherapy; HDR-BT, high dose-rate brachytherapy; EBRT, external beam radiotherapy; SBRT, stereotactic body radiotherapy; CIRT, carbon ion radiotherapy. Figure S4: Meta-analysis of the time to prostate-specific antigen (PSA) nadir after radiotherapy. ES, effect size; CI, confidence interval; LDR-BT, low dose-rate brachytherapy; HDR-BT, high dose-rate brachytherapy; EBRT, external beam radiotherapy; SBRT, stereotactic body radiotherapy; CIRT, carbon ion radiotherapy.
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cancers-12-02180-t001_Table 1

###### 

Papers that report PSA bounce after radiotherapy included in the meta-analysis.

  Author              Year   *n*    Modality      Age                 Risk Group   ADT           Follow Up (M)      Bounce (%)   Amplitude (ng/mL)       Time to Bounce (M)   Nadir (ng/mL)         Time to Nadir (M)   Reference
  ------------------- ------ ------ ------------- ------------------- ------------ ------------- ------------------ ------------ ----------------------- -------------------- --------------------- ------------------- -----------------------------
  Merrick et al.      2002   218    EBRT+LDR-BT   66 ± 7              L, I         No            46 ± 14            23.9         0.9 (0.3--3.0)          19 ± 9               NA                    NA                  \[[@B6-cancers-12-02180]\]
  Patel et al.        2004   295    LDR-BT        NA                  L, I         Yes, partly   38 (24--68)        28.0         0.5 (0.2--4.1)          19 (8--40)           NA                    NA                  \[[@B7-cancers-12-02180]\]
  Coen et al.         2004   101    LDR-BT        NA                  L, I         No            54 (38--86)        39.6         0.6 (0.2--7.5)          18 (7--71)           NA                    NA                  \[[@B8-cancers-12-02180]\]
  Zietman et al.      2005   190    EBRT          NA                  L, I, H      Yes, all      60 (40--75)        39.0         0.9 (0.5--1.8)          28 (17--42)          NA                    NA                  \[[@B9-cancers-12-02180]\]
  Ciezki et al.       2006   162    LDR-BT        68 (45--83)         L, I, H      Yes, partly   73                 46.3         NA                      15 (2--57)           NA                    NA                  \[[@B10-cancers-12-02180]\]
  Horwitz et al.      2006   4839   EBRT          NA                  L, I, H      No            75                 18.6         NA                      NA                   NA                    NA                  \[[@B11-cancers-12-02180]\]
                             2693   LDR-BT        NA                  L, I, H      No            60                 17.5         NA                      NA                   NA                    NA                  
  Toledano et al.     2007   295    LDR-BT        60--65              L, I         Yes, partly   40 (9--66)         49.0         0.8, mean (0.1--4.1)    19, mean (6--58)     NA                    NA                  \[[@B12-cancers-12-02180]\]
  Bostantic et al.    2007   57     LDR-BT        65 ± 6              L            No            62 ± 10            14.0         0.4                     18 ± 9               NA                    NA                  \[[@B13-cancers-12-02180]\]
                             46     LDR-BT        63 ± 7              L            No            64 ± 12            45.7         0.4                     22 ± 11              NA                    NA                  
                             29     LDR-BT        66 ± 6              L            Yes, all      67 ± 12            20.7         0.4                     6 ± 6                NA                    NA                  
                             32     LDR-BT        67 ± 5              L            Yes, all      62 ± 12            28.1         0.4                     18 ± 8               NA                    NA                  
  Crook et al.        2007   292    LDR-BT        64 (45--80)         L, I         No            44 (8--81)         40.0         0.7 (0.2--11.7)         15 (3--29)           0.05 (0.01--0.20)     40                  \[[@B14-cancers-12-02180]\]
  Mitchell et al.     2008   205    LDR-BT        62, mean (43--75)   L, I         No            45 (24--85)        37.0         0.9 (0.2--5.8)          14 (1--40)           NA                    NA                  \[[@B15-cancers-12-02180]\]
  Makarewicz et al.   2009   121    EBRT+HDR-BT   68 (47--78)         L, I         No            81 (60--106)       31.0         0.2, mean (0.2--0.7)    14 (7--26)           0.8 (0.01--2.1)       NA                  \[[@B16-cancers-12-02180]\]
  King et al.         2009   41     SBRT          66 (48--83)         L            No            33 (6--45)         29.0         0.3 (0.2--2.4)          18 (12--33)          0.3 (0.03--2.6)       NA                  \[[@B17-cancers-12-02180]\]
  Pinkawa et al.      2010   135    EBRT          71 (52--83)         L, I, H      Yes, partly   67 (9--97)         20.0         NA                      NA                   NA                    NA                  \[[@B18-cancers-12-02180]\]
                             66     EBRT+HDR-BT   72 (63--81)         L, I, H      Yes, partly   75 (7--98)         23.0         NA                      NA                   NA                    NA                  
                             94     LDR-BT        69 (49--81)         L, I         Yes, partly   76 (8--101)        42.0         NA                      NA                   NA                    NA                  
  Caloglu et al.      2011   820    LDR-BT        68 (45--87)         L, I, H      Yes, partly   58 (36--123)       30.1         NA                      17 (2--68)           NA                    NA                  \[[@B19-cancers-12-02180]\]
  Zwahlen et al.      2011   194    LDR-BT        61 (47--75)         L            No            60 (23--109)       50.0         0.5 (0.2--8.3)          14 (0--70)           0.1 (0.0--3.5)        NA                  \[[@B20-cancers-12-02180]\]
  Aaltomaa et al.     2011   535    LDR-BT        64 (42--80)         L, I, H      Yes, partly   69 (15--131)       27.4         NA                      NA                   NA                    NA                  \[[@B21-cancers-12-02180]\]
  Beriwal et al.      2012   155    EBRT+LDR-BT   65 ± 7              L, I, H      Yes, partly   36 (24--60)        29.7         0.6, mean (0.2--2.3)    12, mean (6--36)     NA                    NA                  \[[@B22-cancers-12-02180]\]
  Hinnen et al.       2012   975    LDR-BT        66 ± 6              L, I, H      Yes, partly   78 (27--215)       32.0         1.7 (1.0--2.8, IQR)     19 (12--24, IQR)     NA                    12 (6--15)          \[[@B23-cancers-12-02180]\]
  Mazeron et al.      2012   198    LDR-BT        67 (49--80)         L, I         No            63 (36--119)       35.9         1.0 ± 1.0               18 ± 9               NA                    NA                  \[[@B24-cancers-12-02180]\]
  Bolzicco et al.     2013   71     SBRT          72 (52--82)         L, I, H      Yes, partly   36 (6--76)         12.6         NA                      23 (18--30)          0.4                   36                  \[[@B25-cancers-12-02180]\]
  Chen et al.         2013   100    SBRT          69 (48--90)         L, I, H      Yes, partly   27 (16--42)        31.0         0.5 (0.2--2.2)          15 (3--21)           0.4 (0.1--1.9)        24                  \[[@B26-cancers-12-02180]\]
  Katz et al.         2013   304    SBRT          69, mean (45--88)   L, I, H      Yes, partly   60 (8--78)         17.0         0.5                     30                   0.1                   60                  \[[@B27-cancers-12-02180]\]
  King et al.         2013   1100   SBRT          70 (44--91)         L, I, H      Yes, partly   36                 16.0         0.5 (0.2--5.29)         NA                   NA                    NA                  \[[@B28-cancers-12-02180]\]
  Mehta et al.        2013   157    HDR-BT        63 (42--90)         L, I         Yes, partly   55                 43.0         0.6 (0.2--4.5)          13 (0.6--64)         NA                    NA                  \[[@B29-cancers-12-02180]\]
  Lee et al.          2014   29     SBRT          72 (50-86)          L, I, H      Yes, partly   41 (12--69)        28.0         0.6 (0.3--1.5)          9                    0.3 (0.003--1.7)      23                  \[[@B30-cancers-12-02180]\]
  Nishihara et al.    2014   116    LDR-BT        66 (51--80)         L, I         No            42 (18--77)        40.5         0.4 (0.2--5.6)          17 (8--36)           NA                    NA                  \[[@B31-cancers-12-02180]\]
  Vu et al.           2014   120    SBRT          68 (47--88)         L, I, H      Yes, partly   24 (18--78)        28.0         0.5                     9                    NA                    NA                  \[[@B32-cancers-12-02180]\]
  Patel et al.        2014   114    EBRT+HDR-BT   68 (48--79)         L, I         No            66 (24--124)       39.0         0.4 (0.2--6.6)          16 (3--76)           0.1 (0.01--1.7)       53 (8--118)         \[[@B33-cancers-12-02180]\]
  Waters et al.       2014   74     EBRT, hopo    68 ± 5              L            No            36, min            31.1         0.6                     NA                   NA                    NA                  \[[@B34-cancers-12-02180]\]
                             58     EBRT          66 ± 5              L            No            36, min            20.7         0.3                     NA                   NA                    NA                  
                             230    LDR-BT        64 ± 6              L            No            36, min            29.6         0.6                     NA                   NA                    NA                  
  Kole et al.         2015   175    SBRT          69 (48--85)         L, I, H      No            36                 36.2         NA                      15 (1--42)           0.3 (0.02--1.8)       30 (3--48)          \[[@B35-cancers-12-02180]\]
  Kishan et al.       2015   130    SBRT          69 (44--87)         L, I         No            40 (12--93)        30.8         0.5 (0.2--3.6)          14 (3--43)           NA                    NA                  \[[@B36-cancers-12-02180]\]
                      2015   220    HDR-BT        64 (43--84)         L, I         No            49 (12--94)        39.5         0.6 (0.2--7.1)          10 (3--63)           NA                    NA                  
                      2015   89     EBRT          66 (52--85)         L, I         No            27 (12--90)        21.3         0.5 (0.2--7.6)          13 (3--66)           NA                    NA                  
  Leduc et al.        2015   274    LDR-BT        62 (45--76)         L            Yes, partly   50 (24--126)       31.0         1.0 (0.2--12.4)         12 (6--37)           NA                    NA                  \[[@B37-cancers-12-02180]\]
  Quivirin et al.     2015   66     LDR-BT        64 ± 5              L            No            35 (13--72)        36.4         1.8 ± 1.6               12 ± 6               NA                    NA                  \[[@B38-cancers-12-02180]\]
  Engeler et al.      2015   713    LDR-BT        63 (42--82)         L, I, H      Yes, partly   41 (24--132)       24.3         0.7 (0.2--6.1)          12 (6--33)           NA                    NA                  \[[@B39-cancers-12-02180]\]
  Kim et al.          2016   33     SBRT          67 (56--72)         L, I         No            51 (6--71)         30.3         0.2 (0.2--1.3)          10 (6--12)           0.2                   33                  \[[@B40-cancers-12-02180]\]
  Kim et al.          2016   47     SBRT          64 (52--82)         L, I         No            42 (36--78)        51.0         0.5 (0.2--6.2)          9 (3--36)            NA                    36 (11, SD)         \[[@B41-cancers-12-02180]\]
  Phak et al.         2016   35     EBRT+SBRT     69, mean (60--78)   L, I         No            52 (14--74)        28.6         0.2 (0.2--0.5)          11 (6--25)           0.2 (0.04--1.4)       32 (12--51)         \[[@B42-cancers-12-02180]\]
                             42     EBRT          71, mean (61--79)   L, I         No            52 (14--74)        21.4         0.3 (0.2--1.2)          15 (6--30)           0.3 (0.04--1.8)       25 (9--58)          
  Freiberger et al.   2017   94     LDR-BT        69 (49--81)         L, I         Yes, partly   108                42.0         NA                      NA                   0.05, mean            32, mean            \[[@B43-cancers-12-02180]\]
                             66     EBRT+HDR-BT   72 (63--81)         L, I, H      Yes, partly   108                24.0         NA                      NA                   0.1, mean             31, mean            
                             135    EBRT          71 (52--83)         L, I, H      Yes, partly   108                25.0         NA                      NA                   0.5, mean             19, mean            
  Hauck et al.        2017   554    HDR-BT        63 (40--83)         L, I, H      Yes, partly   44 (12--162)       43.2         NA                      11, mean             0.2                   NA                  \[[@B44-cancers-12-02180]\]
  Kindts et al.       2017   192    LDR-BT        60 (50--65)         L, I         Yes, partly   66                 36.0         0.6, mean               18, mean             NA                    NA                  \[[@B45-cancers-12-02180]\]
  Romesser et al.     2017   776    EBRT          61-72, IQR          L, I, H      Yes, partly   110 (83--134)      15.9         0.3 (0.2--0.7, IQR)     24 (16--38, IQR)     NA                    NA                  \[[@B46-cancers-12-02180]\]
  Park et al.         2018   74     SBRT          69 (47--81)         L, I, H      No            63 (12--109)       35.2         0.5 (0.2--2.6)          11 (2--38)           0.1 (0.01--2.6)       47 (1--85)          \[[@B47-cancers-12-02180]\]
  Astrom et al.       2018   623    EBRT+HDR-BT   66 (47--79)         L, I, H      Yes, partly   132 (2--266)       26.0         1.5 (0.3--12.0)         15 (3--103)          NA                    NA                  \[[@B48-cancers-12-02180]\]
  Burchardt et al.    2018   41     LDR-BT        64 ± 7              L, I         Yes, partly   37 ± 8             26.8         0.7 ± 1.1               18 ± 6               0.5 ± 1.1             23 ± 14             \[[@B49-cancers-12-02180]\]
                             53     HDR-BT        67 ± 7              L, I         Yes, partly   33 ± 9             22.6         0.8 ± 0.5               10 ± 4               0.2 ± 0.4             19 ± 14             
  Kubo et al.         2018   352    EBRT+LDR-BT   69 (49--82)         L, I, H      Yes, partly   82 (12--157)       33.2         NA                      20 (3--55)           NA                    NA                  \[[@B50-cancers-12-02180]\]
  Roy et al.          2019   287    SBRT          69 (49--82, IQR)    L, I         Yes, partly   60 (46--106)       31.1         0.6 (0.35--1.61, IQR)   17 (11--25, IQR)     NA                    NA                  \[[@B51-cancers-12-02180]\]
  Jiang et al.        2019   1062   SBRT          68 (63--73, IQR)    L, I         No            66 (36--60, IQR)   26.0         0.5 (0.3--1.0, IQR)     18 (12--31, IQR)     0.2 (0.1--0.3, IQR)   40 (24--66, IQR)    \[[@B52-cancers-12-02180]\]
  Darwis et al.       2020   131    Carbon ions   64, mean (48--80)   L, I         No            60 (39--60)        55.7         0.7 ± 1.0               15 ± 11              0.5 ± 0.3             42 (9--60)          \[[@B53-cancers-12-02180]\]
  Nakai et al.        2020   256    HDR-BT        67 ± 6              L, I         No            91 ± 23            32.3         NA                      19 ± 23              NA                    NA                  \[[@B54-cancers-12-02180]\]
  Slade et al.        2020   4004   LDR-BT        64 ± 6              L, I         No            120                31.8         NA                      NA                   NA                    NA                  \[[@B55-cancers-12-02180]\]
                             473    EBRT          64 ± 6              L, I         No            120                27.7         NA                      NA                   NA                    NA                  

PSA, prostate-specific antigen; EBRT, external beam radiotherapy; LDR-BT, low dose-rate brachytherapy; HDR-BT, high dose-rate brachytherapy; SBRT, stereotactic body radiotherapy; CIRT, carbon ion radiotherapy; NA, not assessable; IQR, interquartile range; L, low risk; I, intermediate risk; H, high risk; ADT, androgen deprivation therapy; M, months. Age, follow-up, and bounce outcomes are shown as mean ± standard deviation or in median (range) unless otherwise stated.

cancers-12-02180-t002_Table 2

###### 

Summary of the results of the meta-analysis of PSA bounce characteristics.

  Modality             Rate of Bounce (%)    Amplitude (ng/mL)     Time to Occurrence (M)   Nadir (ng/mL)         Time to Nadir (M)
  -------------------- --------------------- --------------------- ------------------------ --------------------- ---------------------
  LDR-BT               34 (30--37)           1.7 (1.3--2.0)        18 (17--20)              0.5 (−0.1--1.1)       23 (19--28)
  HDR-BT               36 (29--42)           1.4 (0.7--2.2)        18 (12--25)              0.2 (0.09--0.3)       19 (15--23)
  EBRT                 22 (19--25)           0.8 (0.4--1.2)        24 (20--29)              0.6 (0.5--0.7)        29 (25--32)
  SBRT                 28 (23--32)           1.0 (0.7--1.2)        17 (14--20)              0.6 (0.3--0.8)        38 (26--51)
  EBRT + boost         28 (26--31)           1.0 (0.7--1.4)        18 (14--22)              0.6 (0.4--0.8)        44 (19--70)
  CIRT                 56 (47--64)           0.7 (0.5--1.0)        15 (12--17)              0.5 (0.4--0.6)        42 (40--44)
  Pooled ES            31 (28--33)           1.3 (1.1--1.4)        18 (17--20)              0.5 (0.4--0.6)        35 (28--42)
  *I*^2^, *p* values   93.5% (*p* \< 0.05)   98.3% (*p* \< 0.05)   95.7% (*p* \< 0.05)      99.5% (*p* \< 0.05)   98.4% (*p* \< 0.05)

PSA, prostate-specific antigen; LDR-BT, low dose-rate brachytherapy; HDR-BT, high dose-rate brachytherapy; EBRT, external beam radiotherapy; SBRT, stereotactic body radiotherapy; CIRT, carbon ion radiotherapy; ES, effect size; M, months. Data are means (95% confidence interval).

cancers-12-02180-t003_Table 3

###### 

Summary of the results of the meta-analysis of PSA nadir and time to nadir stratified by bounce occurrence.

  Modality             Nadir (ng/mL)         Time to Nadir (M)                           
  -------------------- --------------------- --------------------- --------------------- ---------------------
                       Bounce                No bounce             Bounce                No bounce
  LDR-BT               NA                    NA                    NA                    NA
  HDR-BT               NA                    NA                    NA                    NA
  EBRT                 0.7 (0.7--0.8)        0.5 (0.5--0.5)        42 (40--43)           29 (28--29)
  SBRT                 0.6 (0.5--0.7)        0.3 (0.3--0.4)        NA                    NA
  EBRT + Boost         0.3 (0.2--0.4)        0.5 (0.4--0.6)        64 (58--70)           54 (48--60)
  CIRT                 0.6 (0.5--0.7)        0.4 (0.3--0.5)        48 (45--50)           36 (33--40)
  Pooled effect size   0.6 (0.3--0.8)        0.5 (0.4--0.6)        50 (42--59)           39 (27--51)
  *I*^2^, *p* values   98.5% (*p* \< 0.05)   95.1% (*p* \< 0.05)   96.6% (*p* \< 0.05)   97.6% (*p* \< 0.05)

PSA, prostate-specific antigen; LDR-BT, low dose-rate brachytherapy; HDR-BT, high dose-rate brachytherapy; EBRT, external beam radiotherapy; SBRT, stereotactic body radiotherapy; CIRT, carbon ion radiotherapy; NA, not assessible; M, months. Data are means (95% confidence interval).

cancers-12-02180-t004_Table 4

###### 

Univariate meta-regression for the proportion and characteristics of bounce.

  Covariates     Rate of Bounce (*n* = 65)   Amplitude (*n* = 37)   Time to Occurrence (*n* = 45)   Nadir (*n* = 15)         Time to Nadir (*n* = 9)                                                                                                                         
  -------------- --------------------------- ---------------------- ------------------------------- ------------------------ ------------------------- ------ -------------------------- ------ ----- ----------------------- ------ ----- -------------------------- ------ ------
  Age            −0.07 (−0.10 to −0.03)      \<0.01                 20.2                            −0.14 (−0.22 to −0.06)   \<0.01                    28.1   0.30 (−0.27 to 0.87)       0.33   1.1   −0.01 (−0.06 to 0.05)   0.78   0.0   −0.32 (−4.82 to 4.18)      0.87   0.0
  Modality                                                                                                                                                                                                                                                                   
  LDR-BT         −0.08 (−0.46 to 0.30)       0.66                   29.7                            0.25 (−0.61 to 1.10)     0.56                      15.4   −5.57 (−11.32 to 0.18)     0.05   5.0   −0.05 (−0.79 to 0.68)   0.88   0.0   −18.96 (−78.66 to 40.74)   0.38   0.0
  HDR-BT         NA                          NA                                                     NA                       NA                               NA                         NA           NA                      NA           NA                         NA     
  EBRT           −0.63 (−1.07 to −0.19)      \<0.01                                                 −0.53 (−1.56 to 0.50)    0.30                             NA                         NA           0.11 (−0.79 to 1.01)    0.78         −13.31 (−72.86 to 46.24)   0.52   
  SBRT           −0.38 (−0.79 to 0.03)       0.07                                                   −0.48 (−1.36 to 0.40)    0.27                             −7.24 (−13.36 to --1.11)   0.02         0.07 (−0.61 to 0.75)    0.82         −3.90 (−52.43 to 44.62)    0.81   
  EBRT + boost   −0.32 (−0.75 to 0.11)       0.14                                                   −0.41 (−1.35 to 0.53)    0.38                             −5.92 (−12.39 to 0.56)     0.07         0.07 (−0.65 to 0.80)    0.82         2.23 (−49.31 to 53.77)     0.89   
  CIRT           0.83 (−0.26 to 1.68)        0.05                                                   −0.70 (−2.24 to 0.83)    0.35                             −9.50 (−20.68 to 1.67)     0.09         NA                      NA           NA                         NA     
  ADT            −0.14 (−0.34 to 0.06)       0.17                                                   −0.20 (−0.63 to 0.22)    0.34                      0.8    0.32 (−2.18 to 2.82)       0.79   0.0   −0.07 (−0.41 to 0.27)   0.66   0.0   −18.10 (−37.28 to 1.08)    0.06   33.8
  Risk group     −0.20 (−0.35 to −0.04)      0.01                   12.2                            −0.23 (−0.62 to 0.15)    0.22                      1.3    1.42 (−0.78 to 3.61)       0.20   0.0   0.02 (−0.21 to 0.24)    0.88   0.0   0.94 (−24.00 to 25.89)     0.93   0.0

LDR-BT, low dose-rate brachytherapy; HDR-BT, high dose-rate brachytherapy; EBRT, external beam radiotherapy; SBRT, stereotactic body radiotherapy; CIRT, carbon ion radiotherapy; ADT, androgen deprivation therapy. NA, not assessible due to collinearity. Data are means (95% confidence interval).
